Philadelphia chromosome-positive chronic myeloid leukemia is a rare type of blood cancer that develops when certain chromosomes in the body’s cells swap pieces during cell division, creating an abnormal chromosome that tells bone marrow to produce too many white blood cells. This genetic mistake affects about nine out of every ten people diagnosed with chronic myeloid leukemia, and while the disease progresses slowly compared to other leukemias, understanding it is essential for anyone facing this diagnosis.

Understanding the Numbers: How Common Is This Disease

Philadelphia chromosome-positive chronic myeloid leukemia, often called Ph+ CML, is relatively uncommon in the general population. In the United States, approximately 9,000 people receive a diagnosis of chronic myeloid leukemia each year^[4]. When we look at all adult leukemia cases combined, chronic myeloid leukemia accounts for roughly 20 percent of them^[1]. Among those diagnosed with CML, the Philadelphia chromosome appears in about 90 percent of cases, making Ph+ CML the most common form of this disease^[1].

The disease shows clear patterns in who it affects. Chronic myeloid leukemia typically strikes older adults, usually appearing during or after middle age^[2]. While it rarely occurs in children, it can develop at any age^[2]. Men face slightly higher risk than women for developing this condition^[7]. The estimated number of deaths from CML in the United States in 2025 is projected to be 1,290^[8], reflecting both the disease burden and the progress made in treatment options.

The relative rarity of this disease means that many people have never heard of it until they or someone they love receives a diagnosis. Understanding that thousands of others share this condition can help newly diagnosed patients feel less isolated as they begin their journey with the disease.

What Causes This Chromosomal Change

The root cause of Philadelphia chromosome-positive chronic myeloid leukemia lies in a specific genetic mistake that happens during the normal process of cell division. Our bodies constantly create new cells to replace old ones, and during this process, cells copy their genetic information contained in chromosomes, which are structures that hold DNA and tell cells how to grow and function^[1].

The Philadelphia chromosome forms when pieces of two different chromosomes break off and swap places. Specifically, part of chromosome 9 breaks away and attaches to chromosome 22, while a piece of chromosome 22 moves to chromosome 9^[1]. This swap creates an abnormal chromosome 22, which doctors call the Philadelphia chromosome. The exchange results in the creation of an abnormal gene called BCR-ABL^[1].

This BCR-ABL gene produces an abnormal protein in the bone marrow called tyrosine kinase, which is an enzyme that can activate bone marrow to produce immature white blood cells^[1]. Normally, the body creates and uses immature white blood cells in a controlled, organized manner. However, with the Philadelphia chromosome present, these immature white blood cells grow out of control. These abnormal cells, often called leukemic white blood cells, begin to multiply rapidly, build up in the bone marrow, and travel throughout the body via the bloodstream^[1].

Who Faces Higher Risk

While scientists do not fully understand what triggers the chromosomal changes that lead to Philadelphia chromosome-positive chronic myeloid leukemia, they have identified several factors that appear to increase a person’s chances of developing the disease. It is important to note that having risk factors does not mean someone will definitely develop CML, and some people with the disease have no known risk factors at all.

Age stands out as one of the most significant risk factors. The disease typically affects older adults, with risk increasing as people age^[7]. The condition rarely appears in children, though it can technically occur at any age^[2]. This age pattern suggests that the genetic mistakes leading to CML may accumulate over time or that older cells are more vulnerable to these changes.

Gender also plays a role in risk. Men develop chronic myeloid leukemia slightly more often than women, though researchers have not determined why this difference exists^[7]. The difference is not dramatic, but it appears consistently in population studies across different countries and ethnic groups.

Exposure to high-dose radiation represents one of the few environmental factors clearly linked to CML risk. People who have been accidentally exposed to very high levels of radiation face increased risk of developing the disease^[7]. This connection was observed in survivors of atomic bomb explosions and in people exposed to nuclear accidents. However, the everyday low-level radiation from medical x-rays or airport scanners has not been shown to increase CML risk.

Unlike some other cancers, chronic myeloid leukemia does not appear to be strongly linked to lifestyle factors such as diet, exercise, smoking, or alcohol consumption. There is no evidence that people can prevent CML through lifestyle changes, which can feel frustrating for patients who want to understand what they might have done differently.

Recognizing the Symptoms

One of the challenging aspects of Philadelphia chromosome-positive chronic myeloid leukemia is that it often develops without causing noticeable symptoms in its early stages. Many people learn they have the disease when routine blood work reveals abnormal results, not because they felt sick^[2]. This silent progression means the disease may be present for some time before diagnosis.

When symptoms do appear, they often develop gradually and can be easily mistaken for less serious conditions. Fatigue represents one of the most common complaints. This is not ordinary tiredness that improves with rest, but rather a persistent feeling of exhaustion that makes daily activities feel overwhelming^[2]. The fatigue occurs because abnormal white blood cells crowd out the bone marrow’s ability to produce healthy red blood cells, leading to anemia, a condition where the blood cannot carry enough oxygen to the body’s tissues^[3].

Weight loss without trying is another warning sign. People with CML may notice their clothes fitting more loosely even though they have not changed their eating habits or increased their physical activity^[2]. This unexplained weight loss can occur because the disease affects the body’s metabolism and the way it uses energy.

Night sweats severe enough to drench nightclothes and bedding may occur^[2]. These are different from mild perspiration and can disrupt sleep, contributing to fatigue. Some people also experience fevers with no obvious cause, as the body may react to the presence of abnormal cells^[2].

Pain or a feeling of fullness below the ribs on the left side is a distinctive symptom that occurs when the spleen, an organ that filters blood and helps fight infection, becomes enlarged^[2]. Leukemic white blood cells can collect in the spleen, causing it to swell. In about 10 percent of patients, the spleen remains normal-sized, but when it does enlarge, it can range from slightly bigger than normal to enormous, sometimes filling much of the abdomen^[8].

Other symptoms may include excessive sweating during sleep, bleeding more easily than normal, feeling full after eating only a small amount of food, loss of appetite, bone pain, and blurry vision caused by bleeding in the back of the eye^[2]. These symptoms occur because the disease affects the production of normal blood cells, including platelets, which are cell fragments that help blood clot and stop bleeding^[3].

Prevention and Early Detection

Unfortunately, there is currently no proven way to prevent Philadelphia chromosome-positive chronic myeloid leukemia. Unlike some cancers that can be reduced through lifestyle changes like quitting smoking, eating a healthy diet, or exercising regularly, CML appears to develop from random genetic mistakes during cell division that cannot be predicted or prevented^[7].

The genetic change that creates the Philadelphia chromosome happens during a person’s lifetime and is not inherited from parents^[6]. Since the exact trigger for this chromosomal swap remains unknown, scientists have not identified specific actions people can take to lower their risk. This lack of prevention strategies can be difficult for patients to accept, as many people naturally want to know what they could have done differently.

There are also no regular screening tests recommended for chronic myeloid leukemia in the general population^[7]. Screening tests are typically performed on people without symptoms to catch disease early, but because CML is relatively rare and there are no simple, inexpensive tests to detect it before symptoms appear, widespread screening is not practical or recommended.

However, people who have been exposed to high-dose radiation may benefit from more careful medical monitoring. If you have a history of significant radiation exposure, discussing this with your healthcare provider can help ensure appropriate follow-up. Additionally, maintaining regular contact with healthcare providers and not dismissing persistent symptoms like unexplained fatigue, weight loss, or night sweats can lead to earlier diagnosis if CML does develop.

Many cases of CML are discovered incidentally during routine blood tests performed for other reasons, such as annual physical examinations or pre-operative screening. This highlights the value of maintaining regular healthcare visits and following through with recommended blood work, even when you feel healthy.

How the Disease Changes the Body

Understanding what happens inside the body when Philadelphia chromosome-positive chronic myeloid leukemia develops helps explain why symptoms occur and why treatment is necessary. The disease fundamentally disrupts the normal process of blood cell production in the bone marrow, which is the soft, spongy tissue inside bones where all blood cells are made^[3].

In healthy bone marrow, stem cells, which are immature cells that can develop into any type of blood cell, divide and mature in a carefully controlled process^[6]. Some stem cells become myeloid stem cells, which further develop into three types of mature blood cells: red blood cells that carry oxygen throughout the body, white blood cells that fight infection, and platelets that help blood clot to stop bleeding^[6].

When the Philadelphia chromosome forms, it creates the BCR-ABL gene, which produces an abnormal tyrosine kinase protein. This protein acts like a switch that is permanently turned on, constantly signaling the bone marrow to produce more and more immature white blood cells called granulocytes, a type of white blood cell that includes neutrophils^[3]. These cells are sometimes also called blast cells because they are immature and not fully developed^[3].

The problem is not just that too many white blood cells are produced, but that these cells are abnormal and do not function properly. They cannot fight infections effectively like healthy white blood cells should^[3]. As these abnormal cells multiply, they take up more and more space in the bone marrow, leaving less room for the production of normal red blood cells and platelets^[3].

This crowding effect leads to a cascade of problems throughout the body. Without enough red blood cells, tissues and organs do not receive adequate oxygen, causing fatigue and weakness. Without enough platelets, the blood cannot clot properly, leading to easy bruising and bleeding. The abnormal white blood cells can also build up in organs like the spleen and liver, causing these organs to swell^[3].

Chronic myeloid leukemia is classified into three phases based on how aggressively the disease is progressing. The chronic phase is the earliest and slowest-progressing stage, where abnormal cells are present in the blood, bone marrow, and sometimes the spleen, but differentiated cells still persist^[1]. Most people, approximately 90 percent, are diagnosed during this chronic phase^[4].

If left untreated or if treatment is not effective, CML can progress to the accelerated phase, where the disease begins to develop more quickly. During this phase, patients experience increased anemia, changes in platelet counts, progressive splenomegaly (enlarged spleen), and increasing numbers of immature cells in the blood and bone marrow^[8].

The most advanced stage is called blast crisis or blast phase, which resembles acute leukemia. During blast crisis, there is a sudden, dramatic increase in immature blast cells in the bone marrow and blood^[3]. This phase is fast-growing and much harder to treat than earlier phases^[4]. Fortunately, advances in treatment have made progression to blast crisis much less common than it once was.